4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy
April 24, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for...
4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer
April 13, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D., M.A., FASRS at the 2023 ARVO Annual Meeting on Thursday, April 27, 2023 at 11:30 a.m. ETPromoted Robert Kim, M.D....
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
March 15, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for...
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
February 22, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and...
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
February 16, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
Company to host live webcast on Wednesday, February 22, at 4:30 p.m. ESTPlatform presentation to be presented at WORLDSymposium™ on Saturday, February 25 EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE...
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
February 02, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
4D-150 Phase 2 SPECTRA clinical trial for diabetic macular edema enrollment is expected to initiate in Q3 2023Initial Phase 1 PRISM clinical trial with 4D-150 for wet age-related macular degeneration...
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
January 09, 2023 09:00 ET
|
4D Molecular Therapeutics, Inc.
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy...
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
November 21, 2022 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
November 14, 2022 07:30 ET
|
4D Molecular Therapeutics, Inc.
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized...